Recent improvements in the field of A₃ adenosine receptor ligands

Bibliography

• FREDHOLM B, ABBRACCHIO MP, BURNSTOCK G et al.: Nomenclature and classification of purinoreceptors. Pharm. Rev. (1994) 46:143–156.
   PubMed Web of Science ®Google Scholar
• ••Fundamentals of classification andnomenclature.
   Google Scholar
• RALEVIC V, BURNSTOCK G: Receptors for purines and pyrimidines. Pharm. Rev. (1998) 50:413–492.
   PubMed Web of Science ®Google Scholar
• ••Fundamentals of classification andnomenclature.
   Google Scholar
• JACOBSON KA, SUZUKI F: Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. Drug Dev. Res. (1996) 39:289–300.
   Web of Science ®Google Scholar
• ••Interesting biological classification.
   Google Scholar
• ABBRACCHIO MP, BRAMBILLA R, KIM HO et al.: G-protein-dependent activation of phospholipase-C by adenosine A3 receptor in rat brain. MoL Pharmacol (1995) 48:1038–1045.
   PubMed Web of Science ®Google Scholar
• •Interesting physiological role.
   Google Scholar
• FREDHOLM BB, IJZERMAN AP JACOBSON KA et al.: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. (2001) 53:527–552.
   Google Scholar
• •Important review of adenosine and its mechanism of transduction.
   Google Scholar
• FREDHOLM BB, ARSLAN G, HALLDNER L et al.: Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol (2000) 362:364–374.
   PubMed Web of Science ®Google Scholar
• JONZON B, NILSSON J, FREDHOLM BB: Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J. Cell. Physiol (1985) 124:451–456.
   PubMed Web of Science ®Google Scholar
• SEXL V, MANCUSI G, HOLLER C et al.:Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells. J. Biol. Chem. (1997) 272:5792–5799.
   PubMed Web of Science ®Google Scholar
• NEARY JT, McCARTY M, KANG Y, ZUNIGA S: Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci. Lett. (1998) 242:159–162.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M: Adenosine — the prototypic neuromodulator. Neurochem. Inter. (1989) 14:249.
   PubMed Web of Science ®Google Scholar
• VON LUBITZ DK, UN RC, POPIK P et al.: Adenosine A3 receptor stimulation and cerebral ischemia. Eur. J. PharmacoL (1994) 263:59–67.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB: Adenosine receptors as targets for drug development. Drug News Perspect (2003) 16:283–289.
   PubMedGoogle Scholar
• •Adenosine ligands and their therapeutic applications.
   Google Scholar
• LINDEN J, TAYLOR HE, ROBEVA A et al.: Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. MoL PharmacoL (1993) 44:524–532.
   PubMed Web of Science ®Google Scholar
• SALVATORE CA, JACOBSON MA, TAYLOR H et al.: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl Acad. Sci. USA (1993) 90:10365–10369.
   PubMed Web of Science ®Google Scholar
• •Complete receptor characterisation.
   Google Scholar
• MAEDA CJ, MIERAU J, LEON I et al.: In vivo role of the adenosine A, receptor. J. PharmacoL Exp. Ther. (1996) 279:1148–1156.
   PubMed Web of Science ®Google Scholar
• ••Complete study of the role of this receptorsubtype.
   Google Scholar
• VON LUBITZ DK, YEW McLENNAN J et al: Stimulation of adenosine A3 receptors in cerebral ischemia. Neuronal death, recovery or both? Ann. IVY Acad. Sci. (1999) 890:93–106.
   PubMed Web of Science ®Google Scholar
• REEVES JJ, HARRIS CA, HAYES BP et al.: Studies on the effects of adenosine A, receptor stimulation on human eosinophils isolated from non-asthmatic or asthmatic donors. Inflamm Res. (2000) 49:666–672.
   PubMed Web of Science ®Google Scholar
• STAMBAUGH K, JACOBSON KA, JIANG JL et al.: A novel cardioprotective function of adenosine Al and A3 receptor during prolonged stimulated ischemia. Am. J. Physiol (1997) 273:H501–H505.
   PubMed Web of Science ®Google Scholar
• RAMKUMAR V, STILES GL, BEAVEN MA et al.: The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. (1993) 268:16887–16890.
   PubMed Web of Science ®Google Scholar
• BLAY J, WHITE TD, HOSKIN DW: The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. (1997) 57:2602–2605.
   PubMed Web of Science ®Google Scholar
• ••Expression of adenosine in tumour mass.
   Google Scholar
• JACOBSON KA, MORO S, KIM YC, LI AH: A3 adenosine receptors: protective versus damaging effects identified using novel agonists and antagonists. Drug. Dev. Res. (1998) 45:113–124.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al.: A3 adenosine receptor ligands; history and perspectives. Med. Res. Rev. (2000) 20:103–128.
   PubMed Web of Science ®Google Scholar
• RORKE S, HOLGATE ST: Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Med. (2002) 1:99–105.
   PubMedGoogle Scholar
• LIM MH, KIM HO, MOON HR et al.: Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands. Bioorg. Med. Chem. Lett. (2003) 13:817–820.
   PubMed Web of Science ®Google Scholar
• •New selective A, adenosine receptor agonists.
   Google Scholar
• DENINNO MP, MASAIVIUNE H, CHENARD LK: 3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. J. Med. Chem. (2003) 46:353–355.
   PubMed Web of Science ®Google Scholar
• GALLO-RODRIGUEZ C, JI XD, MELMAN N et al.: Structure-activity relationship of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J. Med. Chem. (1994) 37:636–646.
   PubMed Web of Science ®Google Scholar
• KIM HO, JI XD, SIDDIQI SM et al.: 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J. Med. Chem. (1994) 37:3614–3621.
   PubMed Web of Science ®Google Scholar
• JEONG LS, JIN DZ, KIM HO et al.: N6-Substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J. Med. Chem. (2003) 46:3775–3777.
   PubMed Web of Science ®Google Scholar
• CAPOZZO G: Optimal use of granulocyte colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia. Oncol Nurs. Forum. (2004) 31:569–576.
   PubMed Web of Science ®Google Scholar
• VOLPINI R, COSTANZI S, LAMBERTUCCI C et al: N6-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human A3 receptor and a starting point for searching A2B ligands. J. Med. Chem. (2002) 45:3271–3279.
   PubMed Web of Science ®Google Scholar
• BARTLETT RT, COOK AF, HOLMAN MJ et al.: Synthesis and pharmacological evaluation of a series of analogues of 1-methylisoguanosine. J. Med. Chem. (1981) 24:947–954.
   PubMed Web of Science ®Google Scholar
• UEEDA M, THOMPSON RD, ARROYO LH, OLSSON RA: 2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. J. Med. Chem. (1991) 34:1334–1339.
   PubMed Web of Science ®Google Scholar
• LI AN, MORO S, FORSYTH N et al.: Synthesis, ComFA analysis and receptor docking of 3,5-diacy1-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J. Med. Chem. (1999) 42:706–721.
   PubMed Web of Science ®Google Scholar
• JI XD, VON LUBITZ D, OLAH M et a/.: Interaction of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem. (1996) 39:781–788.
   Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, LINK R et aL: Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptor. J. Med. Chem. (2000) 43:2227–2238.
   PubMed Web of Science ®Google Scholar
• KIM YC, DE ZWART M, CHANG L et al.: Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J. Med. Chem. (1998) 41:2835–2845.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, CHAKRAVARTY PK, JOHNSON RG et al.: Novel selective non-xanthine selective A3 adenosine receptor antagonists. Drug. Dev. Res. (1996) 37:131.
   Google Scholar
• COLOTTA V, CATARZA D, VARANO F et al.: 1,2,4-Triazolo [4,3-e] quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J. Med. Chem. (2000) 43:1158–1164.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al.: Pyrazolo [4,3-e] 1,2,4. triazolo [1,5-c] pyrimichne derivatives as highly potent and selective human A3 adenosine receptor antagonists. J. Med. Chem. (1999) 42:4473–4478.
   Google Scholar
• BARALDI PG, CACCIARI B, BOREA PA et al.: Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Cuff. Pharm. Des. (2002) 8:2299–2332.
   Google Scholar
• BARALDI PG, TABRIZI MA, FRUTTAROLO F et al.: Recent developments in the field of A3 adenosine receptor antagonists. Drug Dev. Res. (2003) 58:315–329.
   Web of Science ®Google Scholar
• BARALDI PG, FRUTTAROLO, F, TABRIZI MA et al.: Design, synthesis and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J. Med. Chem. (2003) 46:1229–1241.
   PubMed Web of Science ®Google Scholar
• GESSI S, VARANI K, MERIGHI S et al.: Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br. J. Pharmacol. (2001) 134:116–126.
   PubMed Web of Science ®Google Scholar
• MERIGHI S, VARANI K, GESSI S et al.: Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. PharmacoL (2001) 134:1215–1226.
   PubMed Web of Science ®Google Scholar
• GESSI S, VARANI K, MERIGHI S et al.: A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. MoL PharmacoL (2002) 61:415–424.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, HOFFMANN C, CATTABENI F, ABBRACCHIO MP: Adenosine-induced cell death: evidence for receptor-mediated signaling. Apoptosis (1999) 4:197–211.
   PubMed Web of Science ®Google Scholar
• ••Role of adenosine in cell death andsurvival.
   Google Scholar
• KOHNO Y, SET Y, KOSHIBA M et aL: Induction of apoptosis in HL-60 human promyelocytic leukemia cells by selective adenosine A3 receptor agonists. Biochem. Biophys. Res. (1996) 219:904–910.
   PubMed Web of Science ®Google Scholar
• SHNEYVAIS V, NAWRATH H, JACOBSON KA et al.: Induction of apoptosis in cardiac myocyte by an A3 adenosine receptor agonist. Exp. Cell. Res. (2002) 243:383–397.
   Google Scholar